NeuroSense VP to Speak at ALS Drug Summit
Ticker: NRSNW · Form: 6-K · Filed: May 20, 2024 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | May 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: conference-participation, biotech, als
TL;DR
NeuroSense VP speaking at ALS drug summit next week.
AI Summary
NeuroSense Therapeutics Ltd. announced on May 20, 2024, that its Vice President of R&D, Shiran Zimri, Ph.D., will participate in the 3rd Annual ALS Drug Development Summit. This event focuses on advancements in developing treatments for Amyotrophic Lateral Sclerosis (ALS).
Why It Matters
Participation in industry summits like this can raise a company's profile and highlight its research efforts in a critical disease area.
Risk Assessment
Risk Level: low — This filing is an announcement of participation in a conference, not a material financial event.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the report and subject of the announcement.
- Shiran Zimri, Ph.D. (person) — Vice President of R&D at NeuroSense Therapeutics Ltd., speaking at the summit.
- 3rd Annual ALS Drug Development Summit (event) — Conference where the NeuroSense VP will speak.
- May 20, 2024 (date) — Date of the press release and filing.
FAQ
What is the specific date of the 3rd Annual ALS Drug Development Summit?
The filing does not specify the exact dates of the 3rd Annual ALS Drug Development Summit, only that NeuroSense's VP will participate.
What is NeuroSense Therapeutics Ltd.'s primary focus in ALS research?
The filing does not detail NeuroSense's specific research focus in ALS, only that their VP of R&D will speak at a drug development summit.
Is this announcement related to any new drug trial results for NeuroSense?
No, this filing is an announcement of participation in a conference and does not mention any new drug trial results.
What is the significance of the company's participation in this summit?
Participation signifies the company's engagement in the ALS drug development community and provides a platform to potentially share their work or network with peers.
Where is NeuroSense Therapeutics Ltd. headquartered?
NeuroSense Therapeutics Ltd. is headquartered at 11 HaMenofim Street, Building B, Herzliya, Israel.
Filing Stats: 202 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2024-05-20 09:02:02
Filing Documents
- ea0206533-6k_neuro.htm (6-K) — 10KB
- ea020653301ex99-1_neuro.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 15KB
- ex99-1_002.jpg (GRAPHIC) — 28KB
- 0001213900-24-044929.txt ( ) — 89KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: May 20, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 2